Tislelizumab: Clinical Trials

3 trials for Tislelizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 not yet recruiting. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Unknown 2, Not yet recruiting 1
Phase 22Not yet recruiting 1, Unknown 1

Follow Tislelizumab: new trials by email Literature Review of Tislelizumab trials Research Report on Tislelizumab

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
fruquintinib + tislelizumab + FOLFOX - Gastric (Stomach) Cancer, Gastric Adenocarcinoma
Phase 1 / Phase 2Not yet recruitingSixth Affiliated Hospital, Sun Yat-sen University442025-03-012025-03-12
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
Tislelizumab, Paclitaxel, Carboplatin - Esophageal Squamous Cell Carcinoma, Tislelizumab
Phase 1 / Phase 2UnknownJiangsu Cancer Institute & Hospital302022-05-012022-05-27
Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer
Sintilimab - Tislelizumab, Locally Advanced Rectal Cancer
Phase 1UnknownThe First Hospital of Jilin University462021-06-012023-11-18

Narrower conditions

Esophageal Squamous Cell Carcinoma (1)  ·  Stomach Neoplasms (1)

Broader conditions

Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Gastrointestinal Diseases (2)  ·  Gastrointestinal Neoplasms (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Carcinoma (1)  ·  Carcinoma, Squamous Cell (1)  ·  Esophageal Diseases (1)  ·  Esophageal Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms, Glandular and Epithelial (1)  ·  Neoplasms, Squamous Cell (1)  ·  Stomach Diseases (1)

Interventions

tislelizumab (2)  ·  Carboplatin (1)  ·  Folfox protocol (1)  ·  HMPL-013 (1)  ·  Paclitaxel (1)  ·  Radiotherapy (1)  ·  sintilimab (1)

Sponsors

Jiangsu Cancer Institute & Hospital (1)  ·  Sixth Affiliated Hospital, Sun Yat-sen University (1)  ·  The First Hospital of Jilin University (1)

Countries

China (3)

Top investigators

Xiangzhi Zhu, Dr. (1)